Skip to main content
Equibles
GRCE logo

GRCE · Grace Therapeutics, Inc.

Track GRCE — free

Use GRCE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GRCE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.08 +0.04 (+1.96%)
Rebalance outlook locked
Market Cap
$42.91M
Shares
21.04M
Volume · Oct 9 37.8K Avg daily vol (3M) 170.3K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.04 Open$2.05 Day$2.00–2.07 52W close$2.04–5.13 Avg vol 30d138K Short int1.7M · 8.2% float · 19.0d Short vol77% Last earningsFeb 14, 2023 DataJan 2020–Oct 2026 Filing10-Q · Aug 13

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$20.22M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-15.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.4%
Year over year · more shares
Price change (1Y)
-30.5%
Trailing year
Short interest
8.2%
Latest settlement · 19.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.4 · calm Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −31%
below
Price vs 50-day avg −4%
below
RSI (14) 41
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −10%
trailing
6-month return −56%
trailing
YTD return −41%
this year
Relative strength −65%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Distributing
-6% holders QoQ · +9 funds added
Insider flow Accumulating
Net +$214.0K over 90 days · 0% sells
Short interest Falling
8.18% of float · ▼ -2.5% MoM · 19.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
33 holders — mid 2-yr range
Squeeze score 70
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 71%
annualized · 1-yr
Max drawdown −60%
past year
ATR 4.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−31% Bearish
Price vs 50-day avg
−4% Neutral
RSI (14)
41 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Distributing
-6% holders QoQ · +9 funds added
Insider flow Accumulating
Net +$214.0K over 90 days · 0% sells
Short interest Falling
8.18% of float · ▼ -2.5% MoM · 19.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
33 holders — mid 2-yr range
Price context
position in its 52-week range
Range low $2 Now $2 · 0% Range high $5
vs 200-day avg -31% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GRCE
Grace Therapeutics, Inc.
this stock
$42.91M -41.0% -100.0% — 8.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $127.55B +11.0% +46.2% 29.3 1.8%
MRNA
Moderna, Inc.
 $78.65B +568.0% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $76.14B -4.2% +20.8% 18.3 2.1%
CSLLY
Csl Ltd
 $61.58B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
33
% held
19.0%
Net QoQ
-389.9K sh
Top holder
Cerity Partners LLC
Held Float
View
Held by Funds
Fund positions
7
View
Short & Settlement
Short Interest Falling
Shares short
1.7M
Days to cover
19.0d
Change
-44.1K sh
View
Short Volume
Short vol %
77%
As of
Oct 8, 2026
Short Total
View
Fails to Deliver
FTD shares
411
Value
$912
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
50.0%
Week of
Aug 31, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$214.0K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$100.0M
Net income (FY)
$-7.8M
EPS diluted
$-0.47
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 18, 2026
This year
16
View
Exempt Offerings
Offering
$10.0M
Filed
Aug 11, 2026
View
Earnings & Events
Webcasts
Last webcast
Sep 17, 2026
View

Performance

5D 20D 120D MTD YTD
GRCE +0.0% -9.7% -55.7% -5.1% -41.0%
SPY +1.3% +2.1% +9.0% +1.5% +13.5%
vs SPY -1.3% -11.9% -64.6% -6.6% -54.5%
Key facts CIK 1444192 CUSIP 00439U104 Visit website Investor relations